Medicago Planning Vaccine Production Facility in Durham, North Carolina
08/10/2010
"North Carolina's quality of work force, its training programs, and overall understanding of biotech development models were critical factors in our decision to locate in RTP," said Andy Sheldon, president and CEO of Medicago. "We are thrilled with our decision to build our vaccine facility in one of the largest and successful technology parks."
Medicago has received a $21 million research grant from the Defense Advanced Research Projects Agency (DARPA) to improve the production process of H1N1 vaccines. The company's project represents a total investment of more than $32 million in Research Triangle Park.
Project Announcements
Finland-Based ADMARES Plans Waycross, Georgia, U.S. Manufacturing Plant
06/01/2023
Toyota Plans Georgetown, Kentucky, Electric Vehicle Operations
06/01/2023
Ranger Design Establishes North Charleston, South Carolina, Operations
05/31/2023
Austrian-Based Kronospan Expands Oxford, Alabama, Operations
05/30/2023
TiiCKER Expands Grand Rapids, Michigan, Operations
05/30/2023
Hanon Systems Establishes Bulloch County, Georgia, Operations
05/26/2023
Most Read
-
Is a Flurry of Fads Shaping Economic Development Policy?
Q2 2023
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
Nearshoring — North America’s Next Factory
Q2 2023
-
Front Line: Water Supply Increasingly Affecting Location Decisions
Q2 2023
-
First Person: Labor Crunch in the Construction Industry
Q2 2023
-
Life Science Conversions in Real Estate
Q2 2023
-
19th Annual Consultants Survey: Clients Challenged by Tight Labor Market, Energy Availability
Q1 2023